Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines

Abstract EN

Nowadays, treatment of food allergy only considered the avoidance of the specific food.

However, the possibility of cross-reactivity makes this practice not very effective.

Immunotherapy may exhibit as a good alternative to food allergy treatment.

The use of hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool which could be developed for immunotherapy.

In this study, three mutants of Pru p 3, the principal allergen of peach, were produced based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named as Pru p 3.01, Pru p 3.02, and Pru p 3.03.

Pru p 3.01 showed very similar allergenic activity as the wild type by in vitro assays.

However, Pru p 3.02 and Pru p 3.03 presented reduced IgE binding with respect to the native form, by in vitro, ex vivo, and in vivo assays.

In addition, Pru p 3.03 had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by specific antibodies anti-Pru p 3.

Nevertheless, both Pru p 3.02 and Pru p 3.03 maintained the binding to IgG1 and their ability to activate T lymphocytes.

Thus, Pru p 3.02 and Pru p 3.03 could be good candidates for potential immunotherapy in peach-allergic patients.